A carregar...
High-Dose Infliximab Therapy in Crohn’s Disease: Clinical Experience, Safety, and Efficacy
BACKGROUND: Inadequate response to infliximab [IFX] therapy in Crohn’s disease [CD] may necessitate dose intensification. We evaluated safety and efficacy of high-dose IFX [HD IFX] [greater than 10mg/kg every 8 weeks] in CD and characterized predictors of response to HD IFX intensification. METHODS:...
Na minha lista:
| Publicado no: | J Crohns Colitis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6497242/ https://ncbi.nlm.nih.gov/pubmed/25540149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jju026 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|